Biotechnology
Cancer Prevention
Health

Exact Sciences

$89.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (0.10%) Today
+$0.08 (0.10%) Today

Why Robinhood?

You can buy or sell Exact Sciences and other stocks, options, ETFs, and crypto commission-free!

About

Exact Sciences Corporation Common Stock, also called Exact Sciences, is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. Read More The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Employees
1,977
Headquarters
Madison, Wisconsin
Founded
1995
Market Cap
10.96B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.08M
High Today
$89.71
Low Today
$87.90
Open Price
$88.89
Volume
139.69K
52 Week High
$97.27
52 Week Low
$37.36

Collections

Biotechnology
Cancer Prevention
Health
Technology

News

Yahoo FinanceMar 1

7 Strong Buy Stocks the Street Loves

Which top stocks are Wall Street analysts the most bullish on? I mean stocks with no “hold” or “sell” ratings and a pure “strong buy” analyst consensus. These are the strong buy stocks that make the most compelling investing opportunities and are definitely worth keeping a close eye on. Using TipRanks powerful stock screener, I set out to pinpoint seven stocks that command the unanimous support of the Street. You can customize the screener settings to match your investment strategy. In this case, I selecte...

1,360
Simply Wall StFeb 28

When Can We Expect A Profit From Exact Sciences Corporation (NASDAQ:EXAS)?

Exact Sciences Corporation’s (NASDAQ:EXAS): Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States.

311
PR NewswireFeb 27

Cologuard Helps Screen Two Million People for Colorectal Cancer

MADISON, Wis., Feb. 27, 2019 /PRNewswire/ -- In less than five years, more than two million Americans have screened for colorectal cancer with Cologuard. Exact Sciences Corp., which created the groundbreaking product with Mayo Clinic, processed more than one million Cologuard tests in the last year alone. Nearly half of the people screened with Cologuard had not previously been screened for colorectal cancer, the second leading cause of cancer death in the United States.i "Cologuard is changing how America...

170

Earnings

-$0.49
-$0.39
-$0.28
-$0.18
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.